Kornimate/medical-research-clean huggingface dataset:
ischemic preconditioning in total knee arthroplasty

Conditions: Total Knee Arthroplasty; Ischemic Preconditioning; Postoperative Pain

Summary: the application of a tourniquet for 5 minutes and subsequent reperfusion before actual inflation of the tourniquet for total knee arthroplasty (ischemic preconditioning) decreases the level of local inflammation and therefore postoperative pain in response to reperfusion of the ischemic extremity.

during knee surgery your surgeon routinely uses a device called a tourniquet that allows us to temporarily cut of blood supply to the site of surgery. this helps to reduce blood loss and improves operating conditions. when allowing blood back into your leg at the end of the procedure, debris (bone, fat, tissue breakdown products and cement from the surgery) gets washed out and gains access to the rest of your body. in the vast majority of cases this event bares no major clinical consequences, but can rarely result in signs of inflammation of various body systems. patients with evidence of impaired organ system function such as pre-existing lung and heart disease may be more vulnerable. previous studies suggest that cutting off the blood supply for a short period of time just before a prolonged episode, could lead to a decrease in the extent of tissue breakdown products in this extremity and may thus be associated with a decrease in the inflammation of other organ systems. we propose to study this theory in knee surgery patients by looking at levels of markers of inflammation present in the blood before and after surgery.

Eligibility criteria:
inclusion criteria: * all patients undergoing primary total knee arthroplasty exclusion criteria: * patients who chronically use narcotics (\<1 month). * patients with contraindications (severe peripheral vascular disease, presence of femoral-popliteal bypass grafts, etc.) or no plan for tourniquet use as determined by the clinical care team. * patients who are on corticosteroids prior to their surgery
ultrasound guided quadratus lumborum block for post operative analgesia after hip arthroplasty

Conditions: Pain, Postoperative

Summary: the study evaluates the effectiveness of anterior quadratus lumborum block for post operative analgesia after hip arthroplasty. half of the participants will receive ultrasound guided anterior quadratus lumborum block using 30ml bupivacaine 0.375%, while the other half will not receive the block ( control group).

sensory innervation of the hip region involves branches of the lumbar plexus and sacral plexus. effective post operative analgesia can be approached by blocking the lumbar plexus at the level of the quadratus lumborum muscle. quadratus lumborum block has several approach methods (anterior, lateral, posterior, and intramuscular). anterior quadratus lumborum block also known as transmuscular ql block or ql3, the local anaesthetic (30ml of bupivacaine 0.375%) is injected between the psoas major muscle (pm) and the quadratus lumborum muscle (ql). therefore, the anterior quadratus lumborum block may generate analgesia from t10 to l4 covering the sensory innervation of the hip region.

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists physical status \|-\|\|\| , scheduled to undergo unilateral hip replacement via lateral approach. exclusion criteria: * patient refusal. * history of neurological/neuromuscular, psychiatric, dementia preventing proper comprehension. * coagulation disorders. * history of allergy to the study medication. * infection overlying the injection site.
determinants of oral morphine answer among obese patients before and after gastric bypass

Conditions: Obesity

Summary: the bariatric surgery is widely used to treat obesity. roux-en-y gastric bypass is one of the most frequently surgical methods performed and combines restrictive and malabsorptive procedures. different data suggest that this surgery may modify drug absorption and we think it would be clinically relevant to describe the consequences of gastric bypass on drug systemic exposure in obese patients, since no data on the comparison between the pharmacokinetics (pk) of a drug before and after surgery are available and help to predict the drugs posology.the investigators decided to study the morphine because there is a lack of information about the pk, pharmacodynamics (pd) et pharmacogenetics (pg) of morphine in obese subjects, in contrary with anaesthetic drugs. this is a drug with a narrow therapeutic range frequently prescribed in obese patients.


Eligibility criteria:
inclusion criteria: * patients aged between 18 and 60 years old. * patients with morbid obesity (imc \> 40 kg/m²) or severe obesity (imc=35-40 kg/m²) with co morbidities (sleep apnea syndrome or hypertension or steatosis hepatitis) with a favourable decision of a multidisciplinary team for a gastric bypass. * patient agreeing to go 3 times for a one day hospitalisation in the urt of the lariboisière hospital for the morphine pk/pd. * patient with a previous medical examination. * patient giving its well-informed and free consent after information. exclusion criteria: * diabetes * concomitant sedative, antidepressive or analgesic treatments or drugs unadvised with morphine * untreated sleep apnea syndrom, hypoxia (pao2\ 45mmhg), anaemia \ 3n

Keywords: obesity gastric bypass morphine pharmacokinetic absorption
efficacy and safety of ospemifene in the treatment of moderate to severe vaginal dryness and vaginal pain associated with sexual activity

Conditions: Atrophy; Vaginal Diseases

Summary: the purpose of this study is to determine the safety and efficacy of ospemifene in postmenopausal women experiencing moderate to severe vaginal dryness and vaginal pain associated with sexual activity.


Eligibility criteria:
inclusion criteria: * naturally or surgically menopausal * moderate or severe symptoms of vaginal atrophy * 5% or fewer superficial cells in maturation index of vaginal smear * vaginal ph greater than 5.0 * self reported most bothersome symptom of vaginal dryness or vaginal pain associated with sexual activity, with a severity of moderate or severe at randomization exclusion criteria: * uterine bleeding of unknown origin, uterine polyps or symptomatic and/or large uterine fibroids * current vaginal infection requiring medication * clinically significant abnormal gynecological findings other than signs of vaginal atrophy (e.g. uterine or vaginal prolapse of grade 2 or higher) * previous participation in any other ospemifene study

Keywords: vulvar and vaginal atrophy in postmenopausal women menopausal symptoms vaginal atrophy urogenital atrophy
ai-driven precision diagnostic system for lung cancer based on liquid biopsy

Conditions: Lung Cancer

Summary: the investigators aim to develop an ai-powered precision medicine system based on liquid biopsy that can comprehensively provide lung cancer patients with information on disease stage, histologic subtype, and presence of genetic mutations.


Eligibility criteria:
inclusion criteria (patients) * republic of korea nationality * age ≥ 30 years * lung cancer based on radiologic and/or histopathologic examination * no prior diagnosis of any other cancer and no history of anticancer treatment before the date of blood sample collection exclusion criteria (patients) * history of other cancers before blood collection * prior cancer treatment before blood collection * incomplete clinical data * no consent for sample use inclusion criteria (healthy controls): * republic of korea nationality * no history of any cancer * age ≥ 30 years exclusion criteria (healthy controls): * history of any malignancy * incomplete clinical information or no consent for sample use
a novel nutraceutical to combat post-lyme disease syndrome

Conditions: Post-Lyme Disease Syndrome (PLDS)

Summary: this study will determine the effectiveness of a nutraceutical in treating the lingering effects of lyme disease after antibiotic treatment.

a novel nutraceutical to combat post-lyme disease syndrome will be evaluated during a double blind, placebo controlled study. this study is an expansion of rlp042019 nct04078841 treating post-lyme disease syndrome with acetogenins

Eligibility criteria:
inclusion criteria: 1. a positive two-test methodology using a sensitive enzyme immunoassay (eia) or immunofluorescence assay as a first test, followed by a western immunoblot assay for specimens yielding positive or equivocal results for lyme disease that has been treated with antibiotics but the symptoms persist post treatment. 2. must be able to swallow a mixed powder drink. exclusion criteria: 1 .non positive western blot test. 2. positive western blot test where the individual has not been treated with antibiotics. -

Keywords: lyme
mindfulness-based interventions on psychophysiological recovery and physical functioning after coronary heart surgery

Conditions: Coronary Heart Disease; Mindfulness; Recovery, Psychological; Physical Functioning

Summary: the purpose of this study is to explore the effect of mindfulness on the physical and mental recovery and physical function of patients after coronary heart surgery. methods: convenience sampling was adopted, and patients in the cardiology ward of a northern medical center were selected as the research subjects. eligible subjects were assigned to the experimental group (mindfulness treatment) and the routine care group. the subjects were tested on the day before surgery and on the seventh day after intervention. physical and mental recovery (awareness of inner feelings, anxiety, depression, sleep quality, pain) and physical function (vital capacity, cardiorespiratory endurance, dyspnea after exercise) were measured,

background: if patients with coronary heart disease are not properly controlled and treated, it is not only easy for the disease to relapse and cause angina pectoris, which will prevent the heart from receiving sufficient blood and oxygen supply, leading to an increase in the severity of the disease, and may lead to coronary artery bypass surgery, but postoperative complications may occur. due to reduced respiratory muscle vitality, chest wound pain caused by median sternotomy surgery, and bed rest, resulting in incomplete lung expansion or lung collapse, discomfort due to physiological symptoms, and fear of life-threatening disease, and the risk of disease the uncertainty of treatment causes patients to have negative emotions of anxiety and depression, affecting their sleep quality. purpose: the purpose of this study is to explore the effect of mindfulness on the physical and mental recovery and physical function of patients after coronary heart surgery. methods: convenience sampling was adopted, and patients in the cardiology ward of a northern medical center were selected as the research subjects. eligible subjects were assigned to the experimental group (mindfulness treatment) and the routine care group. the subjects were tested on the day before surgery and on the seventh day after intervention. physical and mental recovery (awareness of inner feelings, anxiety, depression, sleep quality, pain) and physical function (vital capacity, cardiorespiratory endurance, dyspnea after exercise) were measured, and the secondary measurement data were statistically analyzed using spss 29.0 for windows software suite. compare the differences between the two groups in physical and mental recovery and physical function.

Eligibility criteria:
inclusion criteria 18aged patients who are hospitalized and expected to undergo coronary artery bypass surgery those who can cooperate with regular use of induction spirometry exclusion criteria major mental illnesses cognitive impairment long-term bed rest mobility difficulties have deformities of the mouth

Keywords: coronary heart disease surgery, mindfulness
complementary treatment of pg2 to improve clinical benefit response and quality of life in fatigue

Conditions: Quality of Life; Fatigue; Complementary

Summary: the objective of this study is to evaluate the efficacy and safety of pg2 as a complementary treatment to conventional chemotherapy among nsclc patients. in reference to previous studies, "clinical benefit response" and "incidence of grade iii plus vi neutropenia" will be used as the primary endpoints in this study. clinical benefit response is a metric measurement including change in cancer or cancer treatment related "fatigue" which is related to chronic fatigue syndrome (cfs), change in karnofsky performance status and change in weight. the secondary endpoints include patient's global quality of life, and the blood c-reactive protein level which is related to weight change, tumor response, survival time, incidences of myelosuppression (including neutropenia, anemia and thrombocytopenia) and the related g-csf and antibiotics consumption.

this is a multi-center, double-blind, randomized and placebo-controlled study to evaluate complementary effect of pg2 in patients with advanced non-small-cell lung cancer under conventional chemotherapy. patients with stage iiib-iv non-small-cell lung cancer will be screened by inclusion and exclusion criteria and only eligible patients will be enrolled into this study. all enrolled patients will be randomized to pg2 or placebo arm and will receive the cisplatin-based chemotherapy treatment (cisplatin 75mg/m2 and docetaxel 60mg/m2 on day1) during the first three 21-day chemo-cycles. chemo regimen modification is allowable, as usual, in case of disease progression or unacceptable toxicity (see section 6). after randomization, each patient will be administered with pg2 or placebo for 4 days in the 1st week, 3 days in the 2nd week and 3 days in the 3rd week of each chemo-cycle for 3 cycles (dosing schedule in section 6). total 10 doses will be given in each cycle.

Eligibility criteria:
inclusion criteria: * signed the informed consent form. * 18 \~ 75 years old * locally advanced or metastatic with inoperable stage iiib-iv non-small-cell lung cancer. * chemo/radio naive patient * karnofsky performance scores ≧ 70. * adequate bone marrow reserve. * adequate liver function. * adequate renal function. * women with childbearing potential are willing to take contraception measures through the whole treatment course. * life expectancy ≧ 3 months * patient must be willing and able to complete quality of life questionnaires. exclusion criteria: * female patients are pregnant or breast-feeding * patients have brain metastases, stroke or major psychiatric disease. * patients with uncontrolled systemic disease such as active infection, severe heart disease, uncontrollable hypertension or diabetes mellitus. * patients have enrolled or have not yet completed other investigational drug trials within 30 days before randomization.

Keywords: non-small cell lung cancer (nsclc) complementary and alternative medicine (cam) chemotherapy myelosuppression quality of life fatigue eortc qlq-c30 and lc13
premedication with oral midazolam in patients undergoing rigid cystoscopy: a randomized, double-blind, placebo-controlled trial

Conditions: Cystoscopy

Summary: to investigate the efficacy of oral midazolam for patients undergoing rigid cystoscopy in: 1. relieving patient's anxiety and improving satisfaction 2. reducing procedure-related pain 3. facilitating the diagnostic and therapeutic interventions during rigid cystoscopy


Eligibility criteria:
inclusion criteria: * elective rigid cystoscopy * either diagnostic or therapeutic * age between 18 to 80 exclusion criteria: * patients with allergy to midazolam or other benzodiazepine groups * pregnancy * emergency rigid cystoscopy * asa class 3 or above * patients on psychiatric medications * alcoholics

Keywords: diagnostic and therapeutic rigid cystoscopy
studying genes in samples from younger patients with acute megakaryoblastic leukemia

Conditions: Childhood Acute Megakaryocytic Leukemia (M7); Childhood Acute Myeloid Leukemia/Other Myeloid Malignancies

Summary: this laboratory study is looking into genes in samples from younger patients with acute megakaryoblastic leukemia (amkl). studying samples of blood, tissue, and bone marrow from patients with cancer in the laboratory may help doctors learn more about changes that occur in rna and identify biomarkers related to cancer

study subtype: ancillary/correlative observational study model: cohort time perspective: retrospective biospecimen retention: samples with dna biospecimen description: cryopreserved mrna study population description: samples from aaml0531 sampling method: non-probability sample objectives: i. to determine whether nup98/jarid1a expression is a recurrent translocation in nup98-rearranged cases in pediatric acute megakaryoblastic leukemia (amkl). ii. to screen the children oncology group (cog) samples for genetic aberrations in pediatric amkl. outline: cryopreserved specimens are analyzed for nup98 fusion to nsd1, jarid1a, and top1, myeloid/lymphoid or mixed-lineage leukemia (mll)-rearrangements, and other gene expression profiling by reverse transcriptase polymerase chain reaction (rt-pcr) and karyotyping or fluorescence in situ hybridization (fish). results are then compared with each patient's outcome data.

Eligibility criteria:
inclusion criteria: * cryopreserved specimens of pediatric patients diagnosed with acute megakaryoblastic leukemia
composite restorations performed by placing polyethylene fiber

Conditions: Endodontically Treated Teeth

Summary: this study aimed to evaluate the 12-month clinical performance of direct composite restorations by placing polyethylene fibers in different directions in endodontically treated posterior teeth. in this clinical study, clearfil se bond (kuraray/japan) adhesive system, g-aenial universal injectable (gc/tokyo, japan), g-aenial a'chord (gc/tokyo, japan) composites, and polyethylene fiber (ribbond, usa) were used. in the restoration of the teeth included in the study, polyethylene fiber was placed in different directions according to the amount of remaining tooth tissue and cavity preparation. the restorations were divided into three groups according to the direction of fiber placement ('o' shape, mesiodistal i shape, buccolingual i shape) (n=12). restorations were evaluated according to modified usphs criteria in 1st week and 6th months from the placement date. the chi-square test was used for statistical analysis of the difference between the groups, and the cochran q test was used for the significance of the difference between time-dependent changes within each group (p\<0.05).


Eligibility criteria:
inclusion criteria: a patient presenting with; 1. over 18 years of age 2. a normal periodontal status and good general health 3. endodontically treated premolar and molar teeth 4. teeth in contact with the opposing tooth and subjected to normal occlusal forces 5. attend follow-up appointments exclusion criteria: 1. poor oral hygiene status 2. those with severe or chronic periodontitis 3. absence of adjacent and antagonist teeth 4. potential behavioral problems (e.g. bruxism) 5. allergy to any product used in the study 6. systemically unhealthy 7. pregnant and lactating women
effects of magnetic tape on the autonomic nervous system

Conditions: Low Back Pain

Summary: the effect of magnetic tape on pain and autonomic nervous system in subject with lower back pain.

the effects of magnetic nanoparticles in tape applied in the lumbar spine on the autonomic nervous system measured with fully automated pupillometry and on pain in the spine measured with posterior to anterior pressure on the spinous process and the skin pinch test paravertebrally

Eligibility criteria:
inclusion criteria: * current lower back pain with nprs of 5 * between ages 18-65 exclusion criteria: * no lower back pain or pain \<5 on the nprs * not meeting age limit * having condition that prevents the pa procedure * conditions of the nervous system and inability keep eyes open

Keywords: magnetic tape magnetic nano particles pupillometry autonomic nervous system lower back pain pa test skin pinch test
a trial to evaluate the safety and tolerability of brexpiprazole in the treatment of participants with bipolar i disorder.

Conditions: Bipolar I Disorder; Acute Mania

Summary: this study evaluated the safety and evaluate the safety and tolerability of open-label brexpiprazole (2 - 4 mg/day, with a starting dose of 2 mg/day) for the treatment of adult subjects with bipolar i disorder. all participants received a starting dose of brexpiprazole.

while the availability of atypical antipsychotics had increased the therapeutic options available, there remains a need for safer and more effective therapies in the treatment of manic and depressive episodes of bipolar i disorder. brexpiprazole's specific receptor activity profile likely correlates with its established efficacy in schizophrenia and major depressive disorder, and may prove to be an effective target for the treatment of acute mania of bipolar i disorder.

Eligibility criteria:
inclusion criteria (rollover participants from 331-201-00080 \& 331-201-00081 trials) * participants remaining in hospital at the day 21 visit of trial 331-201-00080 or 331-201-00081 were permitted to enroll in the 331-201-00083 trial at the week 3 visit of the double-blind trial if they were planned to be discharged from the hospital before the week 1 visit of trial 331-201-0083. participants not discharged by the week 1 visit of trial 331-201-0083 were withdrawn. * participants who, in the opinion of the investigator, could potentially benefit from administration of oral brexpiprazole for the treatment of bipolar i disorder and who completed 3 weeks of post-randomization treatment in trial 331-201-00080 \& trial 331-201-00081. exclusion criteria (rollover participants from 331-201-00080 \& 331-201-00081 trials) * participants with a major protocol violation during the course of their participation in the double-blind phase 3 trials (331-201-00080 or 331-201-00081).

Keywords: bipolar mania brexpiprazole
luteal phase commencing of growth hormone

Conditions: Infertility

Summary: commencing of growth hormone in luteal phase when follicular cohort for the next cycle is being gathered may increase mature oocytes in poor responder


Eligibility criteria:
inclusion criteria: * poor responder exclusion criteria: * fsh \>20 iu

Keywords: poor responder growth hormone luteal
comparison of argon laser and radiofrequency in trichiasis treatment

Conditions: Trichiasis

Summary: in this clinical trial study,the investigators intend to compare two methods of trichiasis treatment.one by argon laser and the other by radiofrequency then compare the result of these procedures, especially, the investigators would like to compare which of these have less complications such as bleeding,pain,notch in the site of surgery and etc.


Eligibility criteria:
inclusion criteria: * all patients who came to labbafinejad oculoplastic clinic due to trichiasis exclusion criteria: * having a history of entropion * any history of previous laser ,radiofrequency therapy or surgery * more than 50% of the area is involved with trichiasis * more than 10 eye lashes need to be treated

Keywords: argon laser trichiasis radiofrequency patients with trichiasis